Synergistic induction of the inducible nitric oxide synthase (NOS II) gene requires a combination of interferon-g (IFN-g) and lipopolysaccharide (LPS). In this study, we determined whether the induction of IFN-g was required for NOS II-mediated antitumor activity in vivo. Highly metastatic H7 murine pancreatic adenocarcinoma cells were implanted into the subcutis, footpad, and pancreas of syngeneic IFN-g +/+ and IFN-g 7/7 mice. These cells grew and produced metastases and ascites in IFN-g +/+ mice. In sharp contrast, the same tumor cells grew much more aggressively, metastasized more extensively, and produced a larger amount of malignant ascites in IFN-g 7/7 mice. Also, induction of IFN-g correlated with NOS II gene expression and NO production in IFN-g +/+ injected with the tumor cells but not in IFN-g 7/7 mice or IFN-g +/+ mice without tumor challenge. In vitro, only LPS plus IFN-g induced a high level of NO production and cytotoxicity against H7 cells. These data suggested that the tumor cells stimulated IFN-g secretion from host cells, which in turn stimulated NO production by host cells and suppressed tumor growth and metastasis. Oncogene (2001) 20, 6930 ± 6937.
Introduction
Nitric oxide (NO) is a pleiotropic molecule that mediates diverse functions including tumoricidal activity (Nathan, 1992; Moncada and Higgs, 1993; Schmidt and Walter, 1994) . The level of NO production is critical for the extent of NO-mediated antitumor activity (Ambs et al., 1997; Chinje and Stratford, 1997; Tozer and Everett, 1997; Wink et al., 1998; Xie and Fidler, 1998) and depends on the NO synthase (NOS) isoforms and their expression level. Endothelial and neuronal NOS proteins are constitutively expressed and regulated by cellular Ca 2+ , produce a small amount of NO (usually at pM to low nM levels) for only short periods (usually seconds to minutes), and function as an endothelium-derived relaxing factor and neurotransmitter (Ignarro et al., 1987; Jarey and Snyder, 1995) . In sharp contrast, the inducible NOS (iNOS or NOS II) protein is mostly expressed in activated macrophages and endothelial cells (Nathan, 1992; Xie and Fidler, 1998) . Once stimulated, NOS II generates a large amount of NO (usually at mM levels) throughout the life of the active enzyme (usually hours to days) and plays an important role in host defense against pathogens as well as tumorigenic cells (Nathan, 1992; Xie and Fidler, 1998) .
During tumor growth and metastasis, NOS II can be induced by tumor-host interaction. Tumor-associated NO is a result of the NOS activity in both tumor and host cells that in®ltrate and surround the tumor (Xie and Fidler, 1998; Wang et al., 2001a) . In general, macrophages produce much higher levels of NO than do tumor cells or other host cells and are thus the main source of NO production (Nathan, 1992; Xie and Fidler, 1998; Wang et al., 2001a) . Also, the functional NOS II status of tumor-associated macrophages or other in®ltration cells and the availability of NOS II stimuli apparently correlates with dierent NOS II expression levels in dierent tumors (Xie and Fidler, 1998; Wang et al., 2001a) . Therefore, the ultimate eect of tumor-associated NOS II activity may be dictated by multiple sources and levels of NOS II expression. Genetic disruption of the host NOS II gene dierentially aects tumor growth and metastasis Wang et al., 2001a,b) . The sensitivity to NO-mediated cytotoxicity apparently correlates with the outcome. However, the actual level of NOS II expression in tumors is not clear, which may also be a contributing factor. Whether NOS II expression can be further upregulated remains to be determined.
Activation of tumor-associated NOS II inhibits the established liver metastases and tumor suppression correlated with the induction of tumor cell apoptosis (Xie et al., 1995) . This initial observation has been con®rmed by several recent studies (Onier et al., 1999; Kundu et al., 1998) . In addition, elevated tumorassociated NOS II expression also mediates the antitumor activity of interferon-b (IFN-b) (Wang et al., 2001a; Xie et al., 1997) . Furthermore, the antitumor activity of NOS II/NO has been directly demonstrated using both NOS II gene transfaction and retroviral infection, both of which led to signi®cant tumor growth suppression (Xie and Fidler, 1998) . Therefore, it is clear that activation of NOS II in tumor and/or tumor stromal cells may suppress tumor growth and metastasis (Xie and Fidler, 1998) . Nevertheless, a better understanding of the expression and regulation of tumor-associated NOS II activity remains crucial to eectively targeting NOS II/NO for controlling tumor growth and metastasis.
Regulation of NOS II expression involves multiple signal transduction pathways. Recent data have clearly shown that synergistic induction of the NOS II gene occurs at the transcriptional level. The presence of type II IFN (IFN-g) is essential for this induction (Nathan, 1992) . The most prominent synergistic NOS II induction occurs upon treatment using a combination of IFN-g plus LPS, or interleukin-la (IL-la), or tumor necrosis factor-a (TNF-a). The combination among LPS, IL-la, or TNF-a has only an additive eect (Nathan, 1992; Xie and Fidler, 1998) .
In the present study, we demonstrated that IFN-g was induced during tumor growth and metastasis. Production of IFN-g clearly led to the upregulation of the NOS II gene and production of NO at higher level as revealed in mice with or without intact IFN-g gene. The high level of NO output produced cytotoxicity against and suppressed the growth and metastasis of highly metastatic murine pancreatic adenocarcinoma cells. Therefore, physiologically, IFN-g has strong antitumor activity, which is at least in part through induction of the NOS II gene thus providing evidence for the ®rst time that hostderived NO is necessary for IFN-g mediated antitumor activity.
Results

Explosive growth and metastasis of H7 cells in IFN-g
7/7
mice To determine the eect of IFN-g disruption on tumor growth and metastasis, parental PANC02-H7 (H7) cells were injected into the subcutis, footpad, and pancreas of IFN-g +/+ and IFN-g 7/7 C57BL/6J mice. The primary tumors in the subcutis, footpad, and pancreas; metastases in the liver and lungs; and ascites in the peritoneal cavity were determined on indicated days after tumor injection or when the animals became moribund. The quantitative analysis is summarized in Table 1 . We found that H7 cells produced small tumors in the subcutis of IFN-g +/+ mice that were mostly con®ned to the injection site. In sharp contrast, in IFN-g 7/7 mice, the same tumor cells produced much more aggressive subcutaneous tumors that invaded the peritoneal cavity through the abdominal wall and produced extensive carcinomatosis and metastases to the liver and other visceral organs.
In the footpad model, the size of the primary tumors in the IFN-g +/+ and IFN-g 7/7 mice diers; metastasis also diered, but in a more dramatic fashion. H7 cells did not produce either liver or lung metastases in IFN-g +/+ mice, but they did produce liver metastases (two of 10 mice) and lung metastases (10 of 10; Table  1 ) in IFN-g 7/7 mice. These data indicated that disruption of the IFN-g gene aects metastasis more than it does tumor growth.
To provide more physiologic relevance, the tumor cells were orthotopically injected into the pancreas of the mice. H7 cells grew in the pancreas and produced liver metastases and ascites in IFN-g +/+ mice. In contrast, the same cells grew more progressively in the pancreas, produced more numerous liver metastases, and formed larger amount of ascites in IFN-g 7/7 mice. These data indicated that the disruption of IFN-g led to explosive tumor growth, extensive metastasis, and ascites formation. 10/10 2.1 (1.3 ± 3.2)* 10/10 94 (67 ± 4200)* 10/10 3.1 (2.8 ± 5.4)* a Number of mice with tumors in the injection sites, metastases, or ascites/total number of mice. b In this model, the weight of subcutis tumors, number of liver metastases, and amount of ascites were determined 25 days after tumor injection or when the mice became moribund. c In this model, the weight of footpad tumors was determined 14 days after tumor injection; the primary tumors were removed by leg amputation. The number of lung metastases and amount of ascites were determined 35 days after tumor injection or when mice became moribund. In this model, the weight of pancreas tumors, number of liver metastases, and amount of ascites were determined 15 days after tumor injection or when the mice became moribund. H7 cells (2610 5 cells/mouse) were injected into the subcutis, footpad, or pancreas of groups of 10 IFN-g +/+ and IFN-g 7/7 mice. The animals were sacri®ced 15 to 35 days after tumor implantation or when they became moribund, *P50.05 as compared between IFN-g +/+ and IFN-g 7/7 mice Impaired expression of the NOS II gene and production of NO in IFN-g 7/7 mice
To determine the possible mechanisms of tumor promotion in IFN-g 7/7 mice, H7 cells (2610 5 cells/ mouse) were injected into the peritoneum of syngeneic IFN-g +/+ and IFN-g 7/7 mice. Ascites tumor was collected and processed for IFN-g and NOS II mRNA determination by Northern blot analysis. Pancreas was collected from both IFN-g +/+ and IFN-g 7/7 mice without tumor challenge and used as a control. Also, a tumor cell culture was included as a control. As shown in Figure 1a , there was no detectable expression of IFN-g or NOS II mRNA in the pancreas of both IFN-g +/+ and IFN-g 7/7 mice without tumor challenge. However, there was a signi®cant induction of both IFN-g and NOS II mRNA in IFN-g +/+ mice but not IFN-g 7/7 mice after tumor challenge. The elevated levels of IFN-g protein were detected in both serum and ascites of IFN-g
mice injected with tumor cells, but not in those of IFNg 7/7 mice ( Figure 1b ). These data clearly showed that in the IFN-g +/+ mice IFN-g and NOS II genes were both induced by growing tumor cells, whereas in the IFN-g
mice IFN-g gene was not induced and NOS II gene was induced only at low level, suggesting that disruption of the IFN-g gene signi®cantly impaired the expression of the NOS II gene.
In addition, ascites and serum were collected from IFN-g +/+ and IFN-g 7/7 mice and processed for nitrite/ nitrate measurement. Sera were also collected from IFN-g +/+ and IFN-g 7/7 mice without tumor challenge and used as controls. Consistent with the NOS II mRNA expression, a lack of IFN-g induction led to a dramatic decrease in NO production in IFN-g 7/7 mice, as determined by measuring the nitrite/nitrate level in serum and ascites ( Figure 1c ). These data clearly showed that interaction between tumor and host cells led to NOS II expression and NO production, which required the intact IFN-g gene.
Macrophage-mediated and NO-dependent cytostasis requires the participation of IFN-g for synergistic NOS II induction
Tumor-associated NO is a result of the NOS activity in both tumor and host in®ltration cells (Wang et al., 2001a) . The predominant source may be macrophages. To determine whether a lack of IFN-g led to impaired macrophage-mediated, NO-dependent tumoricidal activity, peritoneal macrophages obtained from IFN-g
and IFN-g 7/7 mice were plated into 96-well plates (1610 5 /well) and cultured alone or with H7 cells in medium alone or medium containing 1 mg/ml LPS and/ or 10 U/ml IFN-g in the presence or absence of 2 mM AG. As shown in Figure 2a , LPS and IFN-g alone each produced only slight cytostasis against H7 cells, which correlated with a low level of NO production. In sharp contrast, the combination of LPS and IFN-g produced maximal cytostasis against H7 cells, which correlated directly with a high level of NO production (Figure 2b ). There was no signi®cant dierence in NO Figure 1 Tumor-induced IFN-g and NOS II expression in vivo. H7 cells (2 x 10 5 cells/mouse) were injected into the peritoneum of syngeneic IFN-g +/+ and IFN-g 7/7 mice. (a) Ascites tumor were collected and processed for IFN-g and NOS II mRNA determination by Northern blot analysis. The pancreas was collected from IFN-g +/+ and IFN-g 7/7 mice without tumor challenge and used as a control. A tumor cell culture was also included as a control. Ascites and serum were collected and processed for IFN-g measurement (b), and nitrite/nitrate measurement (c). Sera were also collected from IFN-g +/+ and IFN-g
mice without tumor challenge and used as controls. Note that tumor growth induced the expression of both the IFN-g and NOS II genes in IFN-g +/+ but not IFN-g 7/7 mice, which was correlated with the IFN-g and nitrite/nitrate levels in sera and ascites. *P50.01 induction in vitro between macrophages obtained from IFN-g +/+ mice and those obtained from IFN-g
mice. Finally, the presence of aminoguanidine (AG) inhibited cytostasis, suggesting that NO mediated tumor cytostasis. In addition, little NO production was induced in macrophages by IFN-g or LPS alone. In sharp contrast, NO production was synergistically induced in the macrophages treated with a combination of LPS and IFN-g, suggesting that IFN-g plays an essential role in the induction of NOS II and NO production.
Macrophages as the predominant source of NOS II expression in vivo
In the ®nal set of experiments, NOS II induction and NO production were determined in both macrophages and H7 cells in vitro and in vivo. Macrophages obtained from IFN-g +/+ and IFN-g 7/7 mice and H7 cells were incubated in the presence of 10 U/ml IFN-g, 1 mg/ml LPS, or IFN-g plus LPS; NOS II protein expression and NO production was determined 24 h later. As shown in Figure 3 , NOS II protein expression (Figure 3a ) and NO production ( Figure 3b ) were synergistically induced in macrophages treated with LPS and IFN-g. In contrast, no signi®cant NOS II expression was induced in H7 cells.
To provide direct evidence that NOS II expression was mainly induced in tumor-associated macrophages, H7 cells were injected into the pancreas of IFN-g
and IFN-g 7/7 mice. NOS II expression in the primary tumor growing in the pancreas was ®rst determined by Western blot analysis and NOS II enzymatic activity assay. We found that higher levels of NOS II protein was detected in both ascites and solid tumor tissues from IFN-g +/+ mice as compared to those from IFN-g 7/7 mice ( Figure 4a ). Consistently, there was a high level of NOS II activity in tumors from IFN-g
mice as compared to those from IFN-g 7/7 mice ( Figure  4b) .
Finally, to localize the NOS II expression in the tumor lesion, NOS II protein was determined by immunostaining using an anti-NOS II antibody, and macrophage in®ltration was determined by immuno- mice and H7 cells were incubated in the presence of 10 U/ml IFN-g, 1 mg/ml LPS, or IFN-g plus LPS. NOS II protein expression (a) and NO production (b) were determined 24 h later. Note that there was a synergistic NOS II induction in macrophages treated with LPS and IFN-g. In contrast, there was no signi®cant NOS II protein expression in H7 cells. *P50.01 staining using an anti-macrophage antibody. The tumors that formed in both IFN-g +/+ and IFN-g 7/7
mice were heavily in®ltrated with macrophages. Additionally, signi®cantly lower NOS II expression was detected in the tumors in IFN-g 7/7 mice compared with that in the tumors in IFN-g +/+ mice ( Figure 5 ), which was consistent with the expression of NOS II mRNA, protein, and enzymatic activity, and the production of NO in vivo (Figures 1 and 4) . The NOS II expression pattern was clearly correlated with the macrophage in®ltration pattern, suggesting that NOS II expression was mainly induced in host macrophages ( Figure 5 ).
Discussion
In this study, we have shown that IFN-g and NOS II expression were induced during tumor growth and metastasis. In addition, genetic disruption of the IFN-g gene led to impaired NOS II activation and accelerated tumor growth and metastasis. Because IFN-g is essential for synergistic NOS II induction and highoutput NO production, expression of IFN-g during tumor-host interaction plays a critical role in NOrelated antitumor activity, i.e., IFN-g-mediated antitumor activity involves the production of NO.
IFNs can potentially in¯uence tumor growth through various mechanisms (Krown, 1988; Thomas and Balkwill, 1991; Lokshin et al., 1995; Johns et al., 1992; Zhang et al., 1996; Einhorn and Grander, 1996; Gutterman, 1994) . For example, it has been shown that IFN-g inhibits cellular proliferation and modulates innate and acquired immune function. The antitumor activity of IFN-g depends mainly on the IFN-g-induced changes in gene expression in both tumor and host cells. Also, it has been recognized that a primary target of IFN-g in immunomodulatory function appears to be mononuclear phagocytes (Tannenbaum and Hamilton, 2000; Pestka et al., 1987; Farrar and Schreiber, 1993) . Recent studies by Kaplan et al. (1998) have clearly demonstrated a critical role of IFN-g in host immunosurveillance against transformation and tumor growth. To provide direct evidence of the role of IFN-g in NO-mediated antitumor activity, highly metastatic H7 cells, which do not express NOS II at a signi®cant level (data not shown) and have been shown to be nonimmunogenic (Corbett et al., 1984) , were injected into the subcutis, footpad, and pancreas of syngeneic IFN-g +/+ and IFN-g 7/7 mice. Although the H7 cells were tumorigenic and metastatic in the IFN-g +/+ mice, they produced much larger tumors and more metas- mice. NOS II expression in the primary tumors growing in the pancreas was determined by immunostaining using anti-NOS II and macrophage antibodies. Note that H7 tumors were extensively in®ltrated by macrophages, and NOS II protein expression was detected mainly in the in®ltration macrophages tases and ascites in the IFN-g 7/7 mice. The increased tumor growth and metastasis correlated with decreased expression of the NOS II gene in the in®ltration macrophages. These data directly indicated that IFN-g is involved in NOS II expression and NO-mediated antitumor activity. Therefore, the physiologic level of NOS II expression during tumor ± host interaction imposes an inhibitory eect on tumor growth and metastasis.
The eect of NO derived from host cells on tumor growth and metastasis appears to depend on the level of NO production and cellular status of the tumor cells (Ambs et al., 1997; Shi et al., 1999) . In general, the intensity of NO-mediated cytotoxicity depends on their intrinsic sensitivity of tumor cells and the level of NO production (Ambs et al., 1997; Chinje and Stratford, 1997; Tozer and Everett, 1997; Wink et al., 1998; Xie and Fidler, 1998) . One of our recent studies has shown that disruption of the host NOS II gene dierentially in¯uences tumor growth and metastasis, which is related to the sensitivity of tumor cells to NO-mediated cytotoxicity . On the other hand, the level of NO production may depend on the availability of NOS II-inducing cytokines and responsiveness of tumor and host cells. Under in vitro conditions, signi®cant NO induction and NO-mediated cytotoxicity by macrophages exposed to LPS or IFN-g alone do not occur. However, the combination of LPS and IFN-g produces synergistic NO induction and NO-mediated cytotoxicity. In addition to LPS, IFN-g can also synergize with IL-l and TNF existing in the tumor for NO induction. However, any combination of LPS, IL-l, and TNF produces only additive eects. These data suggest that IFN-g plays a key role in synergistic induction of NOS II and NO-mediated antitumor activity.
The source of NO can be tumor and/or host cells. However, tumor cells may not be the major source of NO because H7 cells do not express NOS II at a detectable level in vitro or in vivo Wang et al., 2001a) . NO is therefore most likely produced by host cells, which is consistent with our previous observations (Wang et al., 2001a) , showing that tumor cells stimulate NOS II expression in host cells. In the present study, the tumors that formed in both IFN-g 7/7
and IFN-g +/+ mice were highly in®ltrated with macrophages. Elevated NOS II expression was clearly observed in the tumors that formed in IFN-g +/+ mice, whereas a signi®cantly lower level of expression was found in those in IFN-g 7/7 mice (Figure 4) . The NOS II expression pattern in the tumors was closely correlated with the macrophage in®ltration pattern, suggesting that NOS II was mainly expressed in host macrophages. Therefore, it is possible that IFN-g released from host cells upon interaction with tumor cells and induces NOS II expression mainly in host cells, e.g., macrophages in the presence of other cytokines, such as IL-l and TNF. The low level of NOS II expression in IFN-g 7/7 mice may be due to the presence of these cytokines, which can presumably produce an additive NO induction (Nathan, 1992; Xie and Fidler, 1998 ). Additionally, the elevated level of NOS II expression and NO production may produce diverse eects on tumor growth and metastasis (Ambs et al., 1997; Chinje and Stratford, 1997; Tozer and Everett, 1997; Wink et al., 1998; Xie and Fidler, 1998) . In the present study, an antitumor activity was produced by the expression of NOS II in the host stromal cells, which required IFN-g production in the host cells. Disruption of the IFN-g gene and a lack of physiologic IFN-g production led to decreased NOS II expression and increased tumor growth and metastasis, suggesting that this physiologic level of tumorassociated NOS II activity limits tumor growth and metastasis, i.e., NOS II/NO participates in the immunosurveillance role of IFN-g. Finally, the NOS II expression in human tissue has been controversial, although there are several reports indicating a detectable NOS II protein in human tumor tissues mostly by immunohistochemistry. Therefore, the relevance of our current ®ndings to human diseases remains to be further elucidated.
In summary, we demonstrated that physiologic induction of IFN-g in host cells upon interaction with tumor cells suppresses tumor growth and metastasis in part through the induction of NOS II/NO in host cells such as macrophages. Our data suggest that tumorassociated NO production can be elevated to achieve a more vigorous antitumor status by manipulating NOS II expression.
Materials and methods
Reagents
RPMI-1640 medium, fetal bovine serum (FBS) and phenolextracted Salmonella lipopolysacchride (LPS) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Mouse recombinant interferon-g (IFN-g) (sp. act., 1610 7 U/mg protein) was purchased from Genzyme (Cambridge, MA, USA). All reagents used in tissue cultures were free of endotoxins as determined using the Limulus Amebocyte Lysate assay (sensitivity limit of 0.125 ng/ml) purchased from Associates of Cape Code (Woods Hole, MA, USA).
PANC02-H7 cells and in vitro culture conditions
PANC02 murine pancreatic adenocarcinoma cell line was originally established by Corbett and colleagues by implanting cotton thread-carrying 3-methyl-cholanthrene into the pancreas of C57BL/6 followed by serial s.c. transplantation (Corbett et al., 1984) and was generously provided by Dr James A Nelson (The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA). The highly metastatic PANC02-H7 (H7) cell line was established using an in vivo selection method Wang et al., 2001a) . All tumor cell lines were cultured in RPMI-1640 supplemented with 10% FBS, sodium pyruvate, nonessential amino acids, L-glutamine, and a twofold vitamin solution (Flow Laboratories, Rockville, MD, USA). The cell cultures were maintained in plastic¯asks and incubated in 5% CO 2 -95% air at 378C. Cultures were free of Mycoplasma.
Tumor growth and metastasis
To prepare tumor cells for inoculation, cells in the exponential growth phase were harvested by brief exposure to a 0.25% trypsin/0.02% EDTA solution (wt/vol). Cell viability was determined by trypan blue exclusion, and only single-cell suspensions that were more than 95% viable were used. To evaluate the tumor growth and metastasis, 0.05 ml of a tumor cell suspension (2610 5 cells/mouse) was ectopically or orthotopically injected into the subcutis, footpad or pancreas of anesthetized syngeneic IFN-g +/+ or IFN-g 7/7
C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME, USA) as described previously Wang et al., 2001b) . The animals are sacri®ced 15 to 35 days after tumor implantation or when they became moribund. Primary tumors in the subcutis, footpad, or pancreas; metastases in liver or other organs; and amount of ascites were determined as described previously Wang et al., 2001a) .
NO-mediated cytostasis
Mouse peritoneal exudate macrophages were collected by peritoneal lavage from mice given an intraperitoneal injection of 1. (Pestka et al., 1987) . Cytostasis was calculated according to the formula: cytostasis (%)=[17(B/A)] 6100, in which A is the c.p.m. of the coculture in medium alone and B is the c.p.m. of the coculture in medium containing IFN-g, LPS and/or AG.
Determination of NO production
NO production in vivo was determined by measuring nitrate/ nitrite in the mice's serum and ascites after the conversion of nitrate into nitrite by nitrate reductase (Xie et al., 1997; Wang et al., 2001b) . NO production in vitro was determined by measuring nitrite accumulation in culture supernatants. Nitrite was measured using a microplate assay with Griess reagent (1.0% sulfanilamide, 0.1% naphthylethylene diamine dihydrochloride, and 2.5% H 3 PO 4 ) as described previously (Wang et al., 2001a) . In brief, 50-ml samples were allowed to react with an equal volume of Griess reagent at room temperature for 10 min. The absorbance at 540 nm was monitored using a microplate reader. The nitrite concentration was determined using sodium nitrite as a standard.
Analysis of NOS II and IFN-g gene mRNA expression
NOS II and IFN-g expression were determined using Northern blot analysis essentially as described previously (Xie et al., 1997; Wang et al., 2001a,b) . Brie¯y, cellular mRNA was extracted from tissue or cell cultures using the FastTrack mRNA isolation kit (Invitrogen Co., San Diego, CA, USA). The mRNA (2 mg) was separated electrophoretically on a 1% denaturing formaldehyde agarose gel, transferred to a GeneScreen nylon membrane (DuPont Co., Boston, MA, USA) in a 206 volume of standard saline citrate, and ultraviolet (UV)-crosslinked using a UVStratalinker 1800 (Stratagene, La Jolla, CA, USA). The NOS II and IFN-g cDNA probes were labeled with a-32 Pdeoxycytidine triphosphate using a random labeling kit (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA). Equal loading of mRNA samples was monitored by hybridizing the same membrane ®lter with a human b-actin cDNA probe . The IFN-g concentrations in ascites and serum were further determined by an enzymelinked immunosorbent assay kit (Endogen, Woburn, MA, USA) with a sensitivity of 10 pg/ml.
Analysis of NOS II protein expression
Whole cell lysate was prepared from tissue cultures and standard Western blot analysis was performed as described previously . In brief, the soluble protein in the lysates was separated by centrifugation at 15 000 g for 30 min at 48C. The protein concentration in the lysates was determined and diluted in the lysis buer to 1 mg/ml. After being boiled for 4 min, 20 mg of the samples was loaded and separated on 7.5% SDS ± PAGE and then electrophoretically transferred to a 0.45-mm nitrocellulose membrane (Bio-Rad). The membrane was washed in a blocking buer, incubated in a 1 :500-diluted anti-NOS II antibody (Transduction Laboratories), and treated with a 1 :3000-diluted second antibody (anti-mouse Ig, horseradish peroxidase-linked F(ab') 2 fragment from donkey). The probed protein was detected with an ECL system (Amersham) according to the manufacturer's instructions. Equal protein sample loading was monitored by hybridizing the same membrane ®lter with anti-b-actin antibody. NOS II enzymatic activity of ascites and solid tumor tissues were determined according to our previously published procedure (Xie et al., 1995) .
Immunohistochemistry
Sections (5 mm thick) of frozen tumor tissue were ®xed in chloroform and acetone. Endogenous peroxidase was blocked using 3% hydrogen peroxide in phosphate-buered saline (PBS) for 12 min. The samples were then incubated for 20 min at room temperature with a protein-blocking solution consisting of PBS (pH 7.5) containing 5% normal horse serum and 1% normal goat serum and then incubated at 48C in polyclonal rabbit anti-NOS II or rat F4/80 antibodies. The samples were rinsed and incubated for 1 h at room temperature with peroxidase-conjugated anti-rabbit (NOS II) or rat (F4/80) IgG. The slides were rinsed with PBS and incubated for 5 min with diaminobenzidine (Research Genetics, Huntsville, AL, USA). The sections were then washed three times with distilled water, counterstained with Mayer's hematoxylin (Biogenex Laboratories, San Ramon, CA, USA), and washed once each with distilled water and PBS. Finally, the slides were mounted with a Universal mount (Research Genetics) and examined under a bright-®eld microscope. A positive reaction was indicated by a reddishbrown precipitate in the cytoplasm (Xie et al., 1995 (Xie et al., , 1997 Wang et al., 2001a,b) .
Statistical analyses
The in vitro data were analysed for signi®cance using Students t-test (two-tailed), and the in vivo data were analysed for signi®cance using the Kruskal-Wallis test.
